| |
Cambridge Healthtech Institute, Baltimore Marriott Waterfront, 700 Aliceanna Street, Baltimore, MD 21202
June 3-4, 2003, Workshops on June 2, 2003
PCR—this innovative but elegantly simple technique continues to produce "intriguing" information.
Life-science labs today face enormous challenges of:Engineering new technologies to expedite discovery research
Moving research advances into the clinic
Ramping up molecular technologies for high throughput, without sacrificing reliability and robustness
This Conference is immediately followed by
Gene Quantification June5-6, 2003
"PCR has transformed molecular biology through vastly extending the capacity to identify, manipulate and reproduce DNA. It makes abundant what was once scarce—the genetic material required for experimentations."
-Paul Rabinow, Making PCR, A Story of Biotechnology, University of Chicago Press, 1996
Nucleic acid amplification and detection have become the most widely used technique for conducting biological research. Like the genetic material being exponentially amplified utilization has exploded to an increasing range of applications including molecular biology, environmental science, forensic science, medical science, biotechnology, microbiology, the food industry, diagnostic science, epidemiology, genetics, gene cloning, and more. Microarray development continues to drive these discoveries. New technical developments that improve the performance of nucleic acid amplification and detection, as well as interesting examples of how these techniques are used, are the emphases of this meeting.
|
|
|
Invited Speakers:
|
|
Dr. Charles R. Cantor, Chief Scientific Officer, Sequenom, Inc. Dr. Kimimichi Obata, President, Precision System Science Europe GmbH
Dr. Martin Gilar, Life Sciences Chemistry, Waters Corporation
Dr. Sheng-Guo Fang, Professor, Department of Biology, College of Life Sciences, Zhejiang University
Dr. Quin Chou, Director, Molecular Diagnostics, BioSource International
Dr. John P. Langmore, Founder and Vice President, Commercial Development, Rubicon Genomics, Inc.Dr. Michael Egholm, Vice President of Research, Molecular Staging, Inc
|
|